DOI: https://doi.org/10.22141/2224-0551.14.7.2019.184619

Predicting the effectiveness of choleretic therapy for functional disorders of the gallbladder and the sphincter of Oddi in children

A.E. Abaturov, V.L. Babуch

Abstract


Background. Early detection of functional disorders of the gallbladder and the sphincter of Oddi in children and timely prescription of effective choleric therapy becomes important at the present stage. The purpose of the study was to determine prognostic risk factors for the development of functional disorders of the gallbladder and the sphincter of Oddi in children and to predict the effectiveness of choleric therapy with the addition of ursodeoxycholic acid (UDCA). Materials and methods. Se­venty children with functional disorders of the gallbladder and the sphincter of Oddi aged 4 to 14 years were examined and treated. One hundred and forty clinical-laboratory, molecular-genetic and instrumental-diagnostic parameters were analyzed with the help of Wald’s sequential analysis. Relative risk (RR) and diagnostic coefficient were calculated for each of them. Results. Risk factors for the development of functional disorders of the gallbladder and the sphincter of Oddi were the presence of functional disorders of the gallbladder and the sphincter of Oddi in the father and relatives by maternal lineage (RR is 1.60 and 1.60, respectively), body weight at birth less than 3 kg (RR = 1.95), the onset of the first episode of clinical and paraclinic manifestations at the age of 2 to 6 years (RR = 1.47), the levels of biochemical hepatogram indicators: cholesterol — 43.7–52.0 mmol/l (RR = 1.83), aspartate aminotransferase — 45.0–59.0 n/l (RR = 3.21) and alanine aminotransferase — 28.3–38.0 n/l (RR = 3.21). High efficiency of choleric therapy with the addition of UDCA drugs in functional disorders of the gallbladder and the sphincter of Oddi in children was established (RR = 4.13). The use of UDCA as a part of choleric therapy in the past medical history is of significant importance (RR = 3.67). It was found that after receiving treatment, the levels of expression of microRNA-378f — 3.07–6.14 c.u. (RR = 0.37), microRNA-4311 — 2.51–5.01 c.u. (RR = 0.18), microRNA-4714-3p — 3.19–6.38 c.u. (RR = 0.31) are determined in children as a protective factor. Mathematical models have been developed that can be used to evaluate the risk of developing functional di­sorders of the gallbladder and the sphincter of Oddi in children and the effectiveness of choleric therapy. Conclusions. High efficiency and simplicity in the use of mathematical models for determining the risk of functional disorders of the gallbladder and the sphincter of Oddi in children and predicting the effectiveness of choleric therapy with the addition of ursodeoxycholic acid allow us to re­commend them in the practice of a pediatrician, family physician and pediatric gastroenterologist for timely prescription of rational therapy and checking its effectiveness.


Keywords


functional disorders of the gallbladder and sphincter of Oddi; choleric therapy; ursodeoxycholic acid; prediction; ma­thematical model; children

References


Abaturov AE, Zavgorodniaia NIu, Babich VL. MikroRNK pri zabolevaniiakh gepatobiliarnoi sistemy [MicroRNA for diseases of the hepatobiliary system]. Dnipro: Dominanta Print; 2018: 336 p. (in Russian).

Abaturov AE, Babich VL. The efficacy of applying ursodeoxycholic acid in functional disorders of the gall bladder and Oddi sphincter in children. World of medicine and biology. 2019;(67):7-11. doi: 10.26724/2079-8334-2019-1-67-7. (in Ukrainian).

Abaturov AE, Babich VL. Drug modulation of activity of microRNA generation in functional disorders of the gallbladder and sphincter of Oddi in children. Zdorovʹe rebenka. 2019;14(2):89-95. doi: 10.22141/2224-0551.14.2.2019.165544. (in Ukrainian).

Abaturov AE, Babich VL. The role of microRNA in diseases of the biliary system. Zdorovʹe rebenka. 2017;12(7):841-847. doі: 10.22141/2224-0551.12.7.2017.116191. (in Ukrainian).

Antomonov MIu. Matematicheskaia obrabotka i analiz mediko-biologicheskikh dannykh [Mathematical processing and analysis of biomedical data]. Kyiv: Firma malogo druku; 2006. 558 p. (in Russian).

Babich VL. Application of ursodeoxycholic acid in the treatment of functional disorders of the biliary system. Modern medical technologies. 2017;(34):64-70. (in Ukrainian).

Vakhrushev YaM, Khokhlacheva NA, Mikheeva PS, Suchkova EV. The mechanisms of the disorders of motor-evacuation function of gall bladder and their importance in the development of cholelithiasis. Arhivʺ vnutrennej mediciny. 2018;8(39):53-58. doi: 10.20514/2226-6704-2018-8-1-53-58. (in Russian).

Volosoveс OP, Zubarenko OV, Kryvopustov SP, et al. Pediatrija (gastroenterologija ta patologija rann'ogo viku): navchal'nyj posibnyk [Pediatrics (gastroenterology and pathology of the early age): study guide]. Odessa: Druk Pivden'; 2017. 165-180 pp. (in Ukrainian).

Dvoirin VV, Klimenkov AA. Metodika kontroliruemykh ispytanii [The methodology of controlled trials]. Moscow: Medicine; 1985. 144 p. (in Russian).

Ministry of Нealth of Ukraine. Order on January 29, 2013 № 59. On Adoption Of Unified Clinical Protocols for Medical Care for Children with Digestive Diseases. Available from: https://zakon.rada.gov.ua/rada/show/v0059282-13. Accessed: January 29, 2013. (in Ukrainian).

Castro RE, Ferreira DMS, Afonso MB, et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013 Jan;58(1):119-25. doi: 10.1016/j.jhep.2012.08.008.

Drossman DA, Hasler WL. Rome IV – Functional GI Disoders: Disoders of Gut-Brain Interaction. Gastroenterology. 2016 May;150(6):1257-61. doi: 10.1053/j.gastro.2016.03.035.

Hayes CN, Chayama K. MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma. Int J Mol Sci. 2016 Feb 24;17(3):280. doi: 10.3390/ijms17030280.

Katsushima F, Takahashi A, Sakamoto N, Kanno Y, Abe K, Ohira H. Expression of micro-RNAs in peripheral blood mononuclear cells from primary biliary cirrhosis patients. Hepatol Res. 2014 Oct;44(10):E189-97. doi: 10.1111/hepr.12198.

Kennedy I, Francis H, Meng F, Glaser S, Alpini G.Diagnostic and therapeutic potentials of microRNAs in cholangiopathies. Liver Res. 2017 Jun;1(1):34-41. doi: 10.1016/j.livres.2017.03.003.

Letelier P, Riquelme I, Hernández AH, Guzmán N, Farías JG, Roa JC. Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. Int J Mol Sci. 2016 May 23;17(5). pii: E791. doi: 10.3390/ijms17050791.

Otsuka M, Kishikawa T, Yoshikawa T, et al. MicroRNAs and liver disease. J Hum Genet. 2017 Jan;62(1):75-80. doi: 10.1038/jhg.2016.53.

Panella M, Carotenuto P, Braconi C. MicroRNAs link inflammation and primary biliary cholangitis. Non-coding RNA Investig 2018;2:29. doi: 10.21037/ncri.2018.05.02.

Sakamoto T, Morishita A, Nomura T, at al. Identification of microRNA profiles associated with refractory primary biliary cirrhosis. Mol Med Rep. 2016 Oct;14(4):3350-6. doi: 10.3892/mmr.2016.5606.

Tabibian JH, Lindor KD. Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis. In: Forman LM, editor. Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Developments. Geneva, Switzerland: Springer International Publishing; 2017. 145-152 pp. doi: 10.1007/978-3-319-40908-5_11.






Copyright (c) 2020 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта